INT62824

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 1996
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.94
Pain Relevance 1.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ICAM1) cell adhesion (ICAM1) plasma membrane (ICAM1)
ICAM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
diclofenac 7 99.88 Very High Very High Very High
cytokine 37 97.24 Very High Very High Very High
Inflammation 123 94.12 High High
dexamethasone 45 86.08 High High
chemokine 4 83.56 Quite High
cINOD 7 77.48 Quite High
agonist 7 76.60 Quite High
abdominal pain 1 66.72 Quite High
headache 1 66.08 Quite High
Inflammatory response 11 64.40 Quite High
Disease Link Frequency Relevance Heat
Nicotine Addiction 366 100.00 Very High Very High Very High
INFLAMMATION 142 94.12 High High
Adhesions 194 90.92 High High
Disease 53 77.44 Quite High
Stress 5 75.00 Quite High
Cancer 27 74.40 Quite High
Vomiting 1 67.12 Quite High
Abdominal Pain 1 66.72 Quite High
Headache 1 66.08 Quite High
Atherosclerosis 2 59.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Diclofenac also inhibited LPS-induced increases in E-selectin, ICAM-1 and VCAM-1 mRNAs, indicating that the action of diclofenac is to inhibit synthesis of these molecules.
Negative_regulation (inhibited) of Positive_regulation (increases) of ICAM-1 associated with diclofenac
1) Confidence 0.53 Published 1996 Journal Life Sci. Section Abstract Doc Link 8691982 Disease Relevance 0.33 Pain Relevance 0.38
Of the two catalytic subunits of IKK (IKKalpha and IKKbeta), low concentrations of NAC and mito-Q activated IKKalpha activity, thereby inhibiting the downstream NF-kappaB and ICAM-1 induction by TNF-alpha.
Negative_regulation (inhibiting) of Positive_regulation (induction) of ICAM-1
2) Confidence 0.39 Published 2007 Journal J. Immunol. Section Abstract Doc Link 17237434 Disease Relevance 0.58 Pain Relevance 0.21
However, since embarking on this study an independent research group [133] has reported that the elevation of serum sICAM-1 in smokers is not abrogated by long-term treatment with a different class of antioxidant molecule-?
Negative_regulation (abrogated) of Positive_regulation (elevation) of sICAM-1 associated with nicotine addiction
3) Confidence 0.37 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 0.73 Pain Relevance 0.11
However, since embarking on this study an independent research group [133] has reported that the elevation of serum sICAM-1 in smokers is not abrogated by long-term treatment with a different class of antioxidant molecule-?
Neg (not) Negative_regulation (abrogated) of Positive_regulation (elevation) of sICAM-1 associated with nicotine addiction
4) Confidence 0.37 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 0.73 Pain Relevance 0.11
Two-hour pre-treatment with 10 mM of both molecules significantly reverted the stimulation of IL-6, IL-8, ICAM-1 and Mcp-1, whereas the effect on I?
Negative_regulation (reverted) of Positive_regulation (stimulation) of ICAM-1
5) Confidence 0.31 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875647 Disease Relevance 0 Pain Relevance 0
These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.
Negative_regulation (decreased) of Positive_regulation (activation) of ICAM-1
6) Confidence 0.28 Published 2009 Journal J. Cell. Biochem. Section Abstract Doc Link 19241441 Disease Relevance 0.26 Pain Relevance 0.17
BOL-303242-X and TA both inhibited LPS-induced increases in cellular levels of IL-1ß and ICAM-1 in HRECs, and a statistically significant reduction of LPS-induced increases in the cellular levels of IL-1ß and ICAM-1 was observed at doses ranging from 0.1 to 10 µM (Figure 4).


Negative_regulation (inhibited) of Positive_regulation (increases) of ICAM-1
7) Confidence 0.26 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2790480 Disease Relevance 0.31 Pain Relevance 0.41

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox